Mylan CEO Bresch Elected Chair Of GPhA
This article was originally published in Scrip
Executive Summary
Mylan's CEO Heather Bresch has been elected chair of the Generic Pharmaceutical Association's (GPhA) board of directors. GPhA is an association that represents generic drug manufacturers and suppliers and Bresch's term as its board's chair will last for one year. Previously she served two one-year terms as chair of GphA in 2004 and 2005 and two one year terms as vice chair in 2003 and 2006.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.